Impact of Opioids and Mu-opioid Receptors on Oncologic Metastasis

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2024 Oct 17

PMID 39417177

Authors

Runjia Wang

Shuai Li

Bomin Wang

Gongming Wang

Hui Zheng

Affiliations

Soon will be listed here.

Abstract

Opioids are the most effective and widely used treatments for acute and chronic pain in patients with cancer. This review focuses on the impact of opioids and mu-opioid receptors (MORs) on the stages of oncologic metastasis. Studies have shown that opioids can facilitate tumor progression and are related to a poor prognosis in patients with cancer. As the primary receptor for opioids, MORs play a significant role in regulating malignant tumor transformation and are involved in processes, such as proliferation, angiogenesis, epithelial-mesenchymal transition (EMT), circulating tumor cells (CTCs) and the tumor microenvironment (TME). While clinical trials have investigated the relationship between opioids and patient prognosis, further research is needed to clarify the relationship between opioids, MORs and metastasis.

References

Gao L, Yang L, He Y, Liu Y, Xu P, Zhang J . MOR promotes epithelial-mesenchymal transition and proliferation via PI3K/AKT signaling pathway in human colorectal cancer. Acta Biochim Biophys Sin (Shanghai). 2022; 55(1):72-80. PMC: 10157524. DOI: 10.3724/abbs.2022114. View

Diaz-Cambronero O, Mazzinari G, Cata J . Perioperative opioids and colorectal cancer recurrence: a systematic review of the literature. Pain Manag. 2018; 8(5):353-361. DOI: 10.2217/pmt-2018-0029. View

Ziche M, Morbidelli L . Nitric oxide and angiogenesis. J Neurooncol. 2001; 50(1-2):139-48. DOI: 10.1023/a:1006431309841. View

Martin J, Charboneau R, Barke R, Roy S . Chronic morphine treatment inhibits LPS-induced angiogenesis: implications in wound healing. Cell Immunol. 2010; 265(2):139-45. PMC: 2950783. DOI: 10.1016/j.cellimm.2010.08.002. View

Gaveriaux-Ruff C, Matthes H, Peluso J, Kieffer B . Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. Proc Natl Acad Sci U S A. 1998; 95(11):6326-30. PMC: 27678. DOI: 10.1073/pnas.95.11.6326. View

Scroope C, Singleton Z, Hollmann M, Parat M . Opioid Receptor-Mediated and Non-Opioid Receptor-Mediated Roles of Opioids in Tumour Growth and Metastasis. Front Oncol. 2022; 11:792290. PMC: 8732362. DOI: 10.3389/fonc.2021.792290. View

Lennon F, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton P . Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012; 116(4):857-67. DOI: 10.1097/ALN.0b013e31824babe2. View

Qi J, Li M, Wang L, Hu Y, Liu W, Long Z . National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data. Lancet Public Health. 2023; 8(12):e943-e955. DOI: 10.1016/S2468-2667(23)00211-6. View

Gerstberger S, Jiang Q, Ganesh K . Metastasis. Cell. 2023; 186(8):1564-1579. PMC: 10511214. DOI: 10.1016/j.cell.2023.03.003. View

10.

Wang X, Zhang S, Jin D, Luo J, Shi Y, Zhang Y . μ-opioid receptor agonist facilitates circulating tumor cell formation in bladder cancer via the MOR/AKT/Slug pathway: a comprehensive study including randomized controlled trial. Cancer Commun (Lond). 2023; 43(3):365-386. PMC: 10009666. DOI: 10.1002/cac2.12408. View

11.

Zhang J, Yao N, Tian S . Morphine Stimulates Migration and Growth and Alleviates the Effects of Chemo Drugs via AMPK-Dependent Induction of Epithelial-Mesenchymal Transition in Esophageal Carcinoma Cells. Biol Pharm Bull. 2020; 43(5):774-781. DOI: 10.1248/bpb.b19-00779. View

12.

Borner C, Hollt V, Kraus J . Mechanisms of the inhibition of nuclear factor-κB by morphine in neuronal cells. Mol Pharmacol. 2012; 81(4):587-97. DOI: 10.1124/mol.111.076620. View

13.

Lennon F, Mirzapoiazova T, Mambetsariev B, Poroyko V, Salgia R, Moss J . The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9(3):e91577. PMC: 3963855. DOI: 10.1371/journal.pone.0091577. View

14.

Lambert A, Pattabiraman D, Weinberg R . Emerging Biological Principles of Metastasis. Cell. 2017; 168(4):670-691. PMC: 5308465. DOI: 10.1016/j.cell.2016.11.037. View

15.

Couto R, Fernandes B . Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer. Curr Drug Res Rev. 2021; 13(2):86-89. DOI: 10.2174/2589977513666210127094222. View

16.

Zylla D, Gourley B, Vang D, Jackson S, Boatman S, Lindgren B . Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer. 2013; 119(23):4103-10. PMC: 3833881. DOI: 10.1002/cncr.28345. View

17.

Cronin-Fenton D . Opioids and breast cancer recurrence. Curr Opin Support Palliat Care. 2019; 13(2):88-93. DOI: 10.1097/SPC.0000000000000426. View

18.

Williams J, Ingram S, Henderson G, Chavkin C, Von Zastrow M, Schulz S . Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev. 2013; 65(1):223-54. PMC: 3565916. DOI: 10.1124/pr.112.005942. View

19.

de Sousa A, Dantas T, Barros Silva P, Martins C, Freire G, Ribeiro Junior H . Analysis of the Immunoexpression of Opioid Receptors and their Correlation with Markers of Angiogenesis, Cell Proliferation and Apoptosis in Breast Cancer. Asian Pac J Cancer Prev. 2021; 22(2):633-640. PMC: 8190334. DOI: 10.31557/APJCP.2021.22.2.633. View

20.

Guan M, Huang Y, Lin X . Sufentanil inhibits the proliferation and epithelial mesenchymal transition of lung cancer cells through Wnt/beta-catenin signaling pathway. Bioengineered. 2022; 13(4):10857-10865. PMC: 9208446. DOI: 10.1080/21655979.2022.2066045. View